NCT05116410 is a Phase 1 clinical trial of HS-20094 in Type 2 Diabetes, sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd..

Who is sponsoring NCT05116410?

NCT05116410 is sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd..

What drugs are being tested in NCT05116410?

Interventions in NCT05116410: HS-20094, Placebo.

What condition does NCT05116410 study?

NCT05116410 studies Type 2 Diabetes.

Is NCT05116410 still recruiting?

NCT05116410 is currently status unknown. Last updated 19 July 2022.

Last reviewed 2022-07-19 · How we verify

NCT05116410

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of HS-20094 in Healthy Participants

Status unknown Phase 1 Last updated 19 July 2022

What this trial tests

Phase 1 trial testing HS-20094 in Type 2 Diabetes in 68 participants. Status unknown.

Timeline

1 November 2021

Primary endpoint
31 October 2022

31 December 2022

Quick facts

Lead sponsor	Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	basic science
Enrollment	68
Start date	1 November 2021
Primary completion	31 October 2022
Estimated completion	31 December 2022
Sites	1 location across China

Drugs / interventions tested

HS-20094 — full drug profile →
Placebo

Conditions studied

Type 2 Diabetes — all drugs for Type 2 Diabetes →

Sponsor

Jiangsu Hansoh Pharmaceutical Co., Ltd. — full company profile →

Who can join

Adults 18 to 55, any sex, with Type 2 Diabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study includes two parts (Single Ascending Dose, SAD; Multiple-Ascending Dose, MAD) and enrolls healthy participants. Participants in SAD accept single subcutaneous (SC) injection of HS-20094 and participants in MAD accept SC injection of HS-20094 once weekly for 4 weeks. The main purpose of this study is to determine 1) The safety of HS-20094; 2) How much HS-20094 gets into the bloodstream and how long it takes the body to get rid of it.3) How HS-20094 affects the levels of blood sugar, insulin and weight.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Signaling pathways in obesity: mechanisms and therapeutic interventions.
Wen X, Zhang B, Wu B, Xiao H, et al · · 2022 · cited 245× · PMID 36031641 · DOI 10.1038/s41392-022-01149-x

Verify or expand the search:

Other trials of HS-20094

Trials testing the same drug.

NCT06901648 — A Study of HS-20094 in Patients With T2DM · Phase 2 · completed
NCT06118021 — A Study of HS-20094 Evaluating Weight Loss in Obese and Overweight Chinese Subjects · Phase 2 · unknown

Other recruiting trials for Type 2 Diabetes

Currently open trials in the same condition.

NCT07053319 — SGLT2i, Pioglitazone, and Ketone Production in T2D · Phase 1 · recruiting
NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07463859 — Effects of Periodontal Treatment Associated With Antimicrobial Photodynamic Therapy on Halitosis in Patients With Diabet · NA · recruiting
NCT07254689 — The Food for Health Study · NA · recruiting
NCT07558863 — Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes · Phase 4 · recruiting

Other Jiangsu Hansoh Pharmaceutical Co., Ltd. trials

Trials by the same sponsor.

NCT07468851 — A Study of HS-10566 in Patients With High-risk Non-muscle-invasive Bladder Cancer Who Are Ineligible for or Refuse Radic · Phase 1, PHASE2 · not yet recruiting
NCT07483437 — A Study of HS-20136-2 in Healthy Participants · Phase 1 · not yet recruiting
NCT07535970 — A Phase I Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of HS-10506 in Healthy Chinese Adult Part · Phase 1 · not yet recruiting
NCT07503015 — Phase 1 Study of HS-20152 in Healthy Participants · Phase 1 · not yet recruiting
NCT07414953 — A Phase Ib Study of HS-10504 Combined Therapy in NSCLC · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05116410 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Jiangsu Hansoh Pharmaceutical Co., Ltd.
Last refreshed: 19 July 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05116410.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing